- Home
- BTAI
as 11-15-2024 4:00pm EST
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 28.7M | IPO Year: | 2018 |
| Target Price: | $5.00 | AVG Volume (30 days): | 458.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.50 - $4.32 | Next Earning Date: | 11-14-2024 |
| Revenue: | $2,276,000 | Revenue Growth: | 83.25% |
| Revenue Growth (this year): | 247.03% | Revenue Growth (next year): | 88.16% |
Stock Insider Trading Activity of BioXcel Therapeutics Inc. (BTAI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| O'Neill Vincent | BTAI | See Remarks | Sep 17 '24 | Sell | $0.55 | 5,556 | $3,055.80 | 19,601 | |
| Rodriguez Javier | BTAI | See Remarks | Sep 17 '24 | Sell | $0.55 | 6,863 | $3,774.65 | 23,770 | |
| Yocca Frank | BTAI | Chief Scientific Officer | Sep 17 '24 | Sell | $0.55 | 7,175 | $3,946.25 | 28,278 | |
| Steinhart Richard I | BTAI | Chief Financial Officer | Sep 17 '24 | Sell | $0.55 | 7,175 | $3,946.25 | 20,279 | |
| Wiley Matthew T. | BTAI | Chief Commercial Officer | Sep 17 '24 | Sell | $0.55 | 6,272 | $3,449.60 | 19,011 | |
| Wiley Matthew T. | BTAI | Chief Commercial Officer | Sep 15 '24 | Sell | $0.69 | 215 | $148.52 | 19,011 | |
| O'Neill Vincent | BTAI | See Remarks | Sep 14 '24 | Sell | $0.69 | 138 | $95.33 | 19,601 | |
| Mehta Vimal | BTAI | CEO and President | Sep 14 '24 | Sell | $0.69 | 1,982 | $1,366.91 | 52,816 | |
| Rodriguez Javier | BTAI | See Remarks | Sep 14 '24 | Sell | $0.69 | 345 | $238.05 | 23,770 | |
| Yocca Frank | BTAI | Chief Scientific Officer | Sep 14 '24 | Sell | $0.69 | 355 | $244.70 | 28,278 |
Latest BioXcel Therapeutics Inc. News
BTAI Breaking Stock News: Dive into BTAI Ticker-Specific Updates for Smart Investing
GuruFocus.com
3 days ago
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...
Thomson Reuters StreetEvents
3 days ago
Q3 2024 BioXcel Therapeutics Inc Earnings Call
Zacks
3 days ago
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
3 days ago
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results
GuruFocus.com
4 days ago
What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings
GlobeNewswire
5 days ago
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
GlobeNewswire
9 days ago
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
Zacks
12 days ago
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know
Compare BTAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BTAI BioXcel Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.